Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Connelly

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The British Journal of Dermatology|May 22, 2001
A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylesterS Gerscher, J P Connelly, G M Beijersbergen Van Henegouwen, et al.
Photochemistry and Photobiology|October 25, 2000
Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivoS Gerscher, J P Connelly, J Griffiths, et al.
Pediatrics|August 1, 1975
Overview statement on medical recordsH C Thompson, S J Barron, J P Connelly, et al.
Disability and Rehabilitation|May 29, 2026
Delivering a hearing and vision support intervention for people with dementia: looking "under the hood" of the SENSE-Cog trial pre- and during the COVID-19 pandemicAlison Holden, Catherine Molony, Chris Armitage, et al.
Pilot and Feasibility Studies|February 12, 2025
SENSE-Cog Residential Care: hearing and vision support for residents with dementia in long-term care in Ireland-protocol for a pilot cluster-randomised controlled trialJ P Connelly, Erin Boland, Brenda Buckley, et al.
The Lancet. Healthy Longevity|October 10, 2024
Hearing and vision rehabilitation for people with dementia in five European countries (SENSE-Cog): a randomised controlled trialIracema Leroi, Christopher J Armitage, Elizabeth M Camacho, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The British Journal of Dermatology|May 22, 2001
A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylesterS Gerscher, J P Connelly, G M Beijersbergen Van Henegouwen, et al.
Photochemistry and Photobiology|October 25, 2000
Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivoS Gerscher, J P Connelly, J Griffiths, et al.
Pediatrics|August 1, 1975
Overview statement on medical recordsH C Thompson, S J Barron, J P Connelly, et al.
Disability and Rehabilitation|May 29, 2026
Delivering a hearing and vision support intervention for people with dementia: looking "under the hood" of the SENSE-Cog trial pre- and during the COVID-19 pandemicAlison Holden, Catherine Molony, Chris Armitage, et al.
Pilot and Feasibility Studies|February 12, 2025
SENSE-Cog Residential Care: hearing and vision support for residents with dementia in long-term care in Ireland-protocol for a pilot cluster-randomised controlled trialJ P Connelly, Erin Boland, Brenda Buckley, et al.
The Lancet. Healthy Longevity|October 10, 2024
Hearing and vision rehabilitation for people with dementia in five European countries (SENSE-Cog): a randomised controlled trialIracema Leroi, Christopher J Armitage, Elizabeth M Camacho, et al.
Pageof 3